Laura Chico

Stock Analyst at Wedbush

(0)
# 4706
Out of 5,298 analysts
244
Total ratings
22.14%
Success rate
-25.87%
Average return
46 Stocks
Name Action Price Target Current % Upside Ratings Updated
TRML Tourmaline Bio
Maintains: Outperform
42 43
12.83 235.15% 2 Mar 14, 2025
VIGL Vigil Neuroscience
Maintains: Outperform
24 13
1.55 738.71% 9 Mar 14, 2025
GOSS Gossamer Bio
Reiterates: Outperform
4 4
0.83 381.93% 4 Mar 14, 2025
OVID Ovid Therapeutics
Maintains: Outperform
4 3
0.28 971.43% 2 Mar 12, 2025
DNTH Dianthus Therapeutic...
Reiterates: Outperform
36 36
16.05 124.3% 6 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
27 28
4.66 500.86% 9 Mar 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 29
20.07 44.49% 14 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
6 6
6.88 -12.79% 9 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
157 147
95.38 54.12% 9 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
46 48
32.42 48.06% 12 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
3.12 412.82% 1 Dec 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
44 45
11.51 290.96% 9 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
19 12
1.09 1000.92% 10 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 38
21.42 77.4% 7 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
29 4
1.81 120.99% 3 Oct 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 25
15.03 66.33% 9 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
22
1.96 1022.45% 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
210 205
122.93 66.76% 16 Sep 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 44
n/a n/a 7 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
40 48
32.54 47.51% 6 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
50 49
29.42 66.55% 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
8 7
3.08 127.27% 4 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 26
11.76 121.09% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
11 11
4.54 142.29% 13 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
42 42
12.03 249.13% 7 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
17 17
5.92 187.16% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
41 41
2.49 1546.59% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 31
14.18 118.62% 5 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 11
0.45 2344.44% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
3.39 47.49% 5 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
330
n/a n/a 6 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
n/a
n/a n/a 5 Sep 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
42
n/a n/a 3 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
24 5
n/a n/a 2 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
9 5
1.22 309.84% 2 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
149
18.56 700.11% 1 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
n/a n/a 1 Sep 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Feb 8, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
33
n/a n/a 1 Sep 18, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Outperform
40
n/a n/a 3 Feb 15, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
240 0
n/a n/a 2 Sep 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Outperform
36 0
n/a n/a 2 Mar 2, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
720
4.93 14504.46% 1 Jan 19, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
n/a
n/a n/a 1 Nov 16, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Strong Buy
280
16.35 1612.54% 1 Apr 21, 2017